Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

被引：0
|
作者：
Yu, Pan
Chen, Fang
Xu, Dan
Yin, Changxin
Liu, Qifa
Sun, Jing
Fan, Zhiping
Wang, Qiang
Liu Xiaoli
Jiang, Qianli
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4522
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [22] Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Guerin, Annie
    Fernandez, Daniel
    Chen, Lei
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (05) : 817 - 827
  • [23] A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st-and 2nd-Generation Tyrosine Kinase Inhibitors for Ph plus Acute Lymphoblastic Leukemia
    Jabbour, Elias J.
    DerSarkissian, Maral
    Duh, Mei Sheng
    McCormick, Nora
    Cheng, Wendy Y.
    McGarry, Lisa J.
    Souroutzidis, Ariadne
    Huang, Hui
    Kantarjian, Hagop M.
    BLOOD, 2016, 128 (22)
  • [24] EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST-AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH plus ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND META-REGRESSION
    Jabbour, E.
    DerSarkissian, M.
    McCormick, N.
    Cheng, W. Y.
    McGarry, L. J.
    Souroutzidis, A.
    Huang, H.
    Duh, M. S.
    HAEMATOLOGICA, 2016, 101 : 33 - 33
  • [25] A Meta-Analysis and Meta-Regression of the Effectiveness of Front-Line Treatment Combinations with Ponatinib versus 1st and 2nd-Generation Tyrosine Kinase Inhibitors for Ph plus Acute Lymphoblastic Leukemia
    Jabbour, Elias
    DerSarkissian, Maral
    Duh, Mei S.
    McCormick, Nora
    Cheng, Wendy Y.
    McGarry, Lisa J.
    Souroutzidis, Ariadne
    Huang, Hui
    Kantarjian, Hagop M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 361 - 361
  • [26] A META-ANALYSIS AND META-REGRESSION OF THE EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST-AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH plus ACUTE LYMPHOBLASTIC LEUKEMIA
    Jabbour, E.
    DerSarkissian, M.
    Duh, M. S.
    McCormick, N.
    Cheng, W. Y.
    McGarry, L.
    Souroutzidis, A.
    Huang, H.
    O'Brien, S.
    Ravandi-Kashani, F.
    Kantarjian, H. M.
    VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
  • [27] Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Wang, Jing
    Jiang, Qian
    Xu, Lan-ping
    Zhang, Xiao-hui
    Chen, Huan
    Qin, Ya-zhen
    Ruan, Guo-rui
    Jiang, Hao
    Jia, Jin-song
    Zhao, Ting
    Liu, Kai-Yan
    Jiang, Bin
    Huang, Xiao-Jun
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (04) : 741 - 750
  • [28] The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Zhang, Yuanfeng
    Feng, Sizhou
    LEUKEMIA RESEARCH, 2021, 109
  • [29] Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
    Marce, Silvia
    Zamora, Lurdes
    Cabezon, Marta
    Xicoy, Blanca
    Boque, Concha
    Fernandez, Cristalina
    Grau, Javier
    Navarro, Jose-Tomas
    Fernandez de Sevilla, Alberto
    Ribera, Josep-Maria
    Feliu, Evarist
    Milla, Fuensanta
    MEDICINA CLINICA, 2013, 141 (03): : 95 - 99
  • [30] Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Konopleva, Marina
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 477 - 484
12345